Digital Diagnostics Inc. They aim to transform the accessibility, affordability, equity, and quality of medical diagnosis and treatment through the application of cutting-edge technology. Their flagship product, LumineticsCore™, is an autonomous AI system that has been cleared by the FDA to provide diagnostic decisions.

This innovative system has demonstrated exceptional performance in real-world clinical settings. LumineticsCore™ is specifically designed to diagnose patients for diabetic retinopathy, including macular edema. Digital Diagnostics takes pride in its commitment to ethical AI healthcare.

They prioritize making their AI systems accessible, ensuring that disease detection is possible even at the point-of-care, thus increasing patient access. Their algorithms are developed with insights from leading medical experts and are based on existing clinical practice guidelines. Additionally, the deep learning-based detectors used in their AI platforms search for the same signs of disease as a clinician, making the AI's decision explainable.

Digital Diagnostics is dedicated to improving patient outcomes and becoming the world leader in developing safe, effective, and equitable AI platforms. Their goal is to make quality healthcare accessible to all, regardless of their geographic location or socio-economic status